June 17, 2020
The Ministry of Health, Labor and Welfare (MHLW) on June 16 ordered label revisions to add new adverse reaction risks for Chugai Pharmaceutical’s cancer agent Avastin (bevacizumab) and Daiichi Sankyo’s Alzheimer’s drug Memary (memantine). Avastin will add “artery dissection” to...read more